Compliance Roadmap for Chinese Manufacturers Entering the Great Britain Market

1. Key takeaways

The core route for Chinese enterprises entering the Great Britain market consists of seven steps: ① product characterisation (reg 2) → ② division and classification determination (Part II/III/IV, Annex IX or List A/B) → ③ route determination (CE transitional provisions or UKCA) → ④ appointment of the UKRP (which must be established in Great Britain) → ⑤ localisation of the technical documentation and the UK Declaration of Conformity → ⑥ MHRA registration (DORS) → ⑦ establishment of the Part 4A post-market surveillance system. Six high-frequency mistakes cluster around the following: misusing EU classification conclusions, assuming that CE recognition exempts UK obligations, mislocating the UKRP, registering later than shipment, overlooking the new annual fee system, and claiming externally that MHRA has approved the product.

The sequence is not decorative. Each step depends on the one before it: classification feeds the route, the route feeds the documentation, the documentation feeds registration, and registration must be complete before the first unit ships. Teams that compress the sequence — for example, starting marketing negotiations before appointing a UKRP, or shipping before registration is confirmed — create findings that are cheap to avoid and expensive to remediate. The seven steps should be run as a single project plan with dependencies, not as parallel workstreams owned by different departments.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): reg 2 (definitions), reg 7 (classification), reg 19B/19C/30A/44ZA/44ZB (routes), reg 7A/19/21A/21B/33A/44 (registration), reg 60 (UKRP), Part 4A regs 44ZC–44ZR (PMS), Part VI reg 53 (fees) and Part VII regs 61–63 (enforcement).
• SI 2023/627 (made on 9 June 2023); SI 2024/1368 (in force on 16 June 2025); SI 2026/197 (in force on 1 April 2026); SI 2021/905 (Northern Ireland).
• GOV.UK news announcement (21 October 2026): indefinite recognition of CE marking and the three obligations it retains.

3. Expert insights

Mistake one: adopting EU MDR classification conclusions directly. General medical devices in the UK are classified under Directive 93/42/EEC Annex IX (the EU uses MDR Annex VIII), and IVDs under 98/79/EC Annex II List A / List B (the EU uses IVDR classes A–D). The same product may land in different classes in the two territories, and classification directly decides PMSR/PSUR frequency and the conformity assessment route. A classification report copied from the EU file is therefore not evidence of UK compliance and should be redone against the UK rules.

Mistake two: reading long-term recognition of CE marking as meaning that the UK does not matter. The decision of 21 October 2026 expressly retains three obligations — UKRP appointment, MHRA registration and PMS — and it does not cover legacy products certified under the MDD/AIMDD/IVDD. CE recognition removes a conformity assessment duplication, not the UK’s post-market architecture, and communications that blur this distinction mislead distributors and customers.

Mistake three: locating the UKRP in Northern Ireland, or appointing a trading partner without assessing conflicts of interest. The UKRP must be established in Great Britain; moreover its statutory duties include ending the legal relationship and notifying MHRA where the manufacturer contravenes its obligations, which is structurally at odds with combining the role with a commercial customer relationship.

Mistake four: registering later than shipping. Registration must be completed before the device is placed on the market (reg 7A, 21A, 33A and others). Devices that are refurbished or relabelled in the company’s own name, system procedure packs and performance evaluation IVDs are all within the scope of mandatory registration and are frequently overlooked.

Mistake five: relying on outdated fee assumptions. From 1 April 2026 the system is an annual fee of £300 per year per GMDN Level 2 category, and reg 53(5) provides that devices must not be placed on the market where fees remain unpaid. The old understanding of a one-off fee of £261 is out of date.

Mistake six: claiming externally that the product has been approved by MHRA, or using the MHRA logo The official guidance makes clear that registration does not constitute any form of endorsement, certification, approval or recognition, and such claims are prohibited.

4. Practical recommendations

GRZAN recommends that Chinese enterprises build a project master plan on the seven steps above, and move the UKRP appointment forward to immediately after step ② — because the UKRP needs time to complete due diligence and sign the letter of designation, while registration and PMS both depend on it being in place. It is also recommended to complete three items of preparation before the product reaches the market: the MORE portal account and rehearsal, the PMS reporting calendar and the calculation of annual fee categories. As a practical estimate, a first-time entrant should allow the longest lead time for UKRP selection and registration, since both involve external counterparties and cannot be compressed by internal effort alone. Each of the three preparatory items removes a known failure mode observed in real market entries, and none of them is technically difficult once the classification and route work has been finished properly.

5. Verification checklist

• □ Product characterisation has been completed under reg 2
• □ Classification has been completed under the UK rules, not under EU conclusions
• □ The route has been determined and the certificate status and expiry points checked
• □ The UKRP has been appointed and is established in Great Britain
• □ Technical documentation and the UK Declaration of Conformity have been localised
• □ MHRA registration has been completed before the device is placed on the market
• □ The Part 4A system has been established and the MORE account is ready
• □ Annual fee categories have been calculated and no fees are unpaid
• □ External materials contain no claim of MHRA approval and no MHRA logo

Regulatory information verified as of 29 October 2026.

• Appointment of the UK Responsible Person (UKRP) and support with signing the letter of authorisation
• Full-process MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee calculation
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) solutions
• Establishment of post-market surveillance (PMS) systems, preparation of PMSR/PSUR and submission of vigilance reports
• Emergency handling of serious adverse incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

For post-market compliance support in the UK market — vigilance reporting, recall management and MHRA inspection response — contact GRZAN at info@grzanglobal.com.